Invasive Decoding and Stimulation of Altered Reward Computations in Depression Patients
Invasive Decoding and Stimulation of Altered Reward Computations in Depression
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lizbeth Nunez Martinez
- Phone Number: (661) 772-6200
- Email: lizbeth.nunezmartinez@mssm.edu
Study Locations
-
-
New York
-
New York, New York, United States, 100119
- Recruiting
- Icahn School of Medicine at Mount Sinai
-
Contact:
- Ignacio Saez, Ph.D.
- Phone Number: 212-523-8829
- Email: ignacio.saez@mssm.edu
-
Principal Investigator:
- Ignacio Saez
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The study will follow clinical criteria for epilepsy patient recruitment for invasive monitoring. As a results, individuals of adults of all ages are expected to be included in this study.
Exclusion Criteria:
- Adults over 80 years of age will be excluded as per concerns of cognitive decline.
- Children under 18 will be excluded from the study since the maturation of frontal lobes continues through adolescence and significant differences in frontal lobe functioning between children younger than 18 and adults are often observed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Participants with depression
Participants with depression to undergo brain stimulation
|
Brain stimulation will be performed after collection of clinical seizure data.
Bipolar stimulation to one or several adjacent electrodes will be applied.
Stimulation design will be either determined prior to testing or designed according to results from neurobehavioral assessments.
Stimulation will consist of biphasic, constant-current trains of stimulation pulses at 100 Hz, with 100 ms pulse width or a sinusoidal wave of a predefined mean band frequency (i.e.
6Hz for θ, 11Hz for α, 20Hz for β, etc.).
Stimulation intensity will be ≤6 mA, consistent with parameters used for clinical mapping, for the duration of the behavioral task or for short (2-3 s) periods of time at given epochs during the task (i.e.
outcome evaluation).
Clinical personnel will be available during stimulation to help monitor stimulation-induced after-discharges; if any are detected, stimulation intensity will be dialed down or terminated.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gambling Task
Time Frame: Day 1
|
Risk attitudes will be evaluated behaviorally.
Patients' behavior will in examined in experimental task (a gambling task) to determine overall proportion of risky choices (gambles) and indifference points (expected gamble value at which the patient is equally likely to choose a gamble or a safe bet).
Score from 0%-100%, with higher percent indicating choosing the risky gamble more often.
|
Day 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Beck's Depression I-II (BDI-II) score
Time Frame: Day 1
|
Self-reported mood questionnaire.
BDI-II total scale 0-63, with higher score indicating more severe depression.
|
Day 1
|
|
Hamilton scales for depression and anxiety (HSDA)
Time Frame: Day 1
|
HSDA comprise the Hamilton Depression Rating Scale (HDRS) and the Hamilton Anxiety Rating Scale (HAM-A).
These are clinician-administered mood and anxiety reports.
HDRS total score range from 0-81 with higher scores indicating greater depression severity.
HAM-A total score range from 0-56, with higher score indicating higher severity.
HRDS full scale from 0-137 where scores of 0-7 indicate normal range, whereas a score of 20 or higher indicates at least moderate severity.
|
Day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ignacio Saez, Ph.D., Icahn School of Medicine at Mount Sinai
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY-17-00258
- 1R01MH124763-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.